Scott Schuetze

14PUBLICATIONS
119CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 26, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

|May 13, 2025
A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma.

Brittany L Siontis, John D Rice, Scott M Schuetze

|Jan 21, 2025
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.

Sandra P D'Angelo, Mihaela Druta, Brian A Van Tine

|Jul 16, 2024
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.

Scott Schuetze, Michael Rothe, Pam K Mangat

|Mar 06, 2024
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.

Scott M Schuetze, Karla V Ballman, Rachel Heise

|Oct 24, 2023
Radiomic-Based Prediction of Lesion-Specific Systemic Treatment Response in Metastatic Disease.

Caryn Geady, Farnoosh Abbas-Aghababazadeh, Andres Kohan

Pageof 3

Frequent Collaborators

5 joint publications

Margaret von Mehren

5 joint publications

Neeta Somaiah

5 joint publications

Brian Andrew Van Tine

4 joint publications

Scott Okuno